

Sodium phosphate injection – Drug shortage

- The [drug shortage](#) of [sodium phosphate](#) injection is ongoing. Sodium phosphate injection has been unavailable for at least 90 days. Fresenius Kabi estimates that product will be available by mid-November 2018. Hospira estimates that product will be available by the second quarter of 2019.
 - Fresenius Kabi’s shortage is due to increased demand.
 - Hospira’s shortage is due to manufacturing delays.
- Sodium phosphate injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Manufacturer	Product Description	NDC #
Fresenius Kabi	Sodium phosphate (phosphorus 15 mmol/mL, 5 mL, sodium 20 mEq/5mL)	63323-170-05
	Sodium phosphate (phosphorus 45 mmol/15 mL, sodium 60 mEq/15 mL)	63323-170-15
Hospira	Sodium phosphate (phosphorous 45 mmol/15 mL, sodium 4 mEq/mL)	00409-7391-72

- Due to the critical shortage of sodium phosphate injection, [Fresenius Kabi](#) is coordinating with the FDA to temporarily import, [Glycophos™ \(sodium glycerophosphate\)](#), an organic phosphate, manufactured in Norway by Fresenius Kabi Norge A/S.
- Glycophos is indicated for adult and infant patients as a supplement in intravenous nutrition to meet phosphate requirements.